VentriPoint Diagnostics Ltd. VPTDF Archives

FridayJun 28, 2013 11:55 am

VentriPoint Diagnostics Ltd. (VPTDF) Offers Superior Solution to Right Heart Analysis

VentriPoint Diagnostics is a Seattle-based provider of a superior heart analysis system. The VentriPoint technology uses conventional 2-dimensional ultrasound data, plus a patented system for analyzing the data called Knowledge-Based Reconstruction (KBR). The result is a 3-dimensional model of the heart, providing critical information regarding things like heart volumes and cardiac output. The VentriPoint system, called Angelo, is of special value for doing what is called right-heart analysis, where the physician needs a clear view of the portion of the heart that pumps blood to the lungs for oxygenation. It is normally difficult to image the right heart using ultrasound,…

MondayJun 24, 2013 9:39 am

VentriPoint Diagnostics Ltd. (VPTDF) Releases Thick Corporate Update, Closing of $500,000 Private Placement

VentriPoint Diagnostics today provided a corporate update and said that it has completed a first closing of the second of two non-brokered private placements. As previously reported, the U.S. FDA had requested additional information concerning the company's 510(k) submission for Pulmonary Arterial Hypertension ("PAH"). In response, VPTDF said it has prepared a detailed statistical plan to obtain the information required in collaboration with the Hospital for Sick Children, Toronto, which will re-analyze the clinical studies. In accordance with its original plans for the clinical trial, VPTDF has completed the collection of an additional 21 clinical cases, which along with the…

FridayJun 21, 2013 11:09 am

VentriPoint Diagnostics Ltd. (VPTDF) VMS™ Technology Notches Favorable Feedback Worldwide

VentriPoint Diagnostics has designed a heart visualization system designed to benefit doctors, patients, and the overall healthcare industry by reducing time and costs of the procedure. The system uses a 2D echo to make a 3D model of the heart to evaluate right heart function and get the same information obtained from an MRI, but in a fraction of the time. As company CEO George Adams recently stated in an interview, the biggest beneficiary of the system is the patient. While cardiac MRIs can take anywhere between 30-90 minutes and take up to three months to get results, with VentriPoint’s…

FridayJun 14, 2013 1:47 pm

Ventripoint Diagnostics, Inc. (VPTDF) Seeks to Expand AngeloVMS™ Applications, Triple Sales by 2014

Ventripoint Diagnostics is the creator of what company management believes to be the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company created the blueprint to achieve its application expansion and goals for continued financial growth, supported by key management. The first applications of the company’s Angelo (VMS™) analysis system are congenital heart disease and pulmonary arterial hypertension. Ventripoint has been granted Canada and Europe (CE Mark) approval for the sale of VMS and is awaiting the U.S.-FDA marketing clearance as well. VMS was developed to address several issues associated with current heart diagnostics and…

ThursdayJun 06, 2013 1:45 pm

Ventripoint Diagnostics Ltd. (VPTDF) Addresses Unmet Medical Need, Offers Outlook for 2013-2014 Sales

Ventripoint has created a diagnostic ultrasound tool to monitor patients with heart disease. Company management believes that VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The product has received Canada and Europe approval (CE Mark) for the sale of VMS™ and the company is now pursuing the U.S.-FDA approval. VMS was developed to address issues with current heart diagnostics. Because of its location between the ribs, the right side of the heart is hard to see with ultrasound and produces “blurry” images of the organ. For this reason, cardiologists order an MRI to…

ThursdayMay 30, 2013 4:15 pm

Ventripoint Diagnostics Ltd. (VPTDF) Appoints New Vice-President of Sales and Marketing

Ventripoint Diagnostics today reported the appointment of Mr. Jerry Gatewood as its Vice-President of Sales and Marketing. Gatewood brings more than 18 years of introducing new medical products with extensive experience in sales and marketing of imaging equipment. He was Global Market Manager for ATL Ultrasound (now Philips Medical Systems), where he created and executed global marketing and market introduction plans, and Director of U.S. Marketing for SonoSite (now part of FujiFilm) where he managed the U.S. marketing team and identified and developed new markets. He was also Director for Global Sales for Merge CAD, where he established, negotiated, and…

TuesdayMay 28, 2013 2:44 pm

VentriPoint Diagnostics Ltd. (VPTDF) Technology Now Used by Hospitals around the World

With much effort, Dr. Florence Sheehan and a team of cardiologists at the University of Washington were able to develop a radically new and more cost effective way of performing critical heart imagery. Through the use of conventional 2-dimensional ultrasound data, easily acquired in a few minutes, together with a patented system known as knowledge-based reconstruction (KBR), the system is able to build a 3D model of the heart and calculate the functional information of heart volumes, cardiac output, and ejection fraction. It’s a revolutionary approach of particular value for performing right-heart analysis, which has traditionally required time consuming and…

TuesdayMay 21, 2013 4:00 pm

Top Lineup for VentriPoint Diagnostics Ltd. (VPTDF)

VentriPoint Diagnostics has developed a technology, now being used in a growing number of hospitals around the world, which effectively replaces costly and time consuming MRI scans for certain types of heart imaging. It has been a challenging task that is now paying off, thanks to the efforts of a dedicated group of people, including the company’s management team: • Dr. George Adams (CEO) is a scientist as well as a long-time entrepreneur and expert financier. Prior to VentriPoint, he was CEO of Amorfix Life Sciences, and continues as Chairman of Semova Corp., both publicly owned companies. Earlier, he was…

TuesdayMay 14, 2013 1:29 pm

VentriPoint Diagnostics Ltd. (VPTDF) and Knowledge Based Reconstruction

VentriPoint Diagnostics, a Seattle based imaging technology company, has developed an important proprietary system that provides a uniquely simple and cost effective way of imaging various heart functions, offering the promise of significantly lower diagnostic and support costs for hospitals and patients. Its current focus is on the diagnosis of congenital heart disease in adults and children, due largely to its remarkable ability for imaging of the right ventricle, but other applications are already being developed. The VentriPont Angelo (VMS™) imaging system is based upon what is called Knowledge Based Reconstruction (KBR), a way of generating an accurate 3-dimensional surface…

TuesdayMay 07, 2013 9:46 am

VentriPoint Diagnostics Ltd. (VPTDF) Prices Private Placements of Common Stock

VentriPoint Diagnostics, developer of a diagnostic ultrasound tool to monitor patients with heart disease, said it intends to complete a non-brokered private placement of up to 1,000 units of the company for $1,000 per unit for gross proceeds of up to $1 million. Each unit will consist of $1,100 principal amount of non-convertible secured debentures that will mature three years from the date of issuance and 2,000 common shares in the capital of the company. The company also reported a non-brokered private placement of up to $800,000 of non-convertible secured debentures in a principal amount of $1,000 per non-unit debenture,…

Site Search

Company Search

Tag: VentriPoint Diagnostics Ltd. VPTDF